Pieter Muntendam
Plus aucun poste en cours
Profil
Pieter Muntendam is the founder of three companies.
He founded Promedex, Inc. in 1996, Vitivity, Inc. in 2001, and scPharmaceuticals, Inc. in 2013.
At Promedex, Inc., he held the titles of Chairman, President & Chief Executive Officer.
At Vitivity, Inc., he held the title of Vice President-Medicine.
At scPharmaceuticals, Inc., he held the titles of President, Chief Executive Officer & Director.
Dr. Muntendam's former jobs include President, Chief Executive Officer & Director at SpringLeaf Therapeutics, Inc. from 2010 to 2014, Chairman-Supervisory Board at DNage BV, Director-Biopharma Healthcare Practice at Netnumina Solutions, Inc. from 2003 to 2004, Vice President-Research & Development at Johnson & Johnson, Chief Medical Officer & Executive Vice President at BG Medicine, Inc. in 2012, Vice President-Care Management at GSK Plc, and Principal at Organon International, Inc. Dr. Muntendam earned a doctorate degree from the University of Leiden.
Anciens postes connus de Pieter Muntendam
| Sociétés | Poste | Fin |
|---|---|---|
DNage BV
 DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | Président | 21/08/2012 |
| BG MEDICINE, INC. | President | 10/01/2012 |
netNumina Solutions, Inc.
 netNumina Solutions, Inc. Information Technology ServicesTechnology Services Netnumina Solutions, Inc. develops management application software solutions. It also provides domain knowledge and unparalleled technology expertise to help clients such as Pfizer, Johnson & Johnson, Aventis, GSK, Fleet, and Fidelity. The company was founded by Imran Sayeed in 1997 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/10/2004 |
| Vitivity, Inc. | Fondateur | 01/04/2003 |
Promedex, Inc.
 Promedex, Inc. Life/Health InsuranceFinance Promedex, Inc. provided disease intervention programs over the Internet. The company was headquartered in Raleigh, NC. | Fondateur | 01/01/2001 |
Formation de Pieter Muntendam
| University of Leiden | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BG MEDICINE, INC. | Health Technology |
| GSK PLC | Health Technology |
| JOHNSON & JOHNSON | Health Technology |
| SCPHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Organon International, Inc.
 Organon International, Inc. Pharmaceuticals: MajorHealth Technology Organon International, Inc. manufactures and markets pharmaceutical products. It develops therapeutics in the fields such as gynecology, fertility, osteoporosis, and anesthesia. The company was founded in 1923 and is located in Roseland, NJ. | Health Technology |
DNage BV
DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | Commercial Services |
Promedex, Inc.
Promedex, Inc. Life/Health InsuranceFinance Promedex, Inc. provided disease intervention programs over the Internet. The company was headquartered in Raleigh, NC. | Finance |
netNumina Solutions, Inc.
netNumina Solutions, Inc. Information Technology ServicesTechnology Services Netnumina Solutions, Inc. develops management application software solutions. It also provides domain knowledge and unparalleled technology expertise to help clients such as Pfizer, Johnson & Johnson, Aventis, GSK, Fleet, and Fidelity. The company was founded by Imran Sayeed in 1997 and is headquartered in Cambridge, MA. | Technology Services |
| Vitivity, Inc. | |
SpringLeaf Therapeutics, Inc.
 SpringLeaf Therapeutics, Inc. Drugstore ChainsRetail Trade SpringLeaf Therapeutics, Inc. is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Excel Venture Management, Flybridge Capital Partners, North Bridge Venture Partners and SR One. | Retail Trade |
